BOARD OF DIRECTORS
Chairman of the board
Professor of Clinical Immunology and Chief Physician at Lund University. Member of the Royal Academy of Sciences (1997). Recipients of national and international awards. Founder and chairman of the noted cancer company HAMLET Pharma.
Helena Lomberg, PhD, has been a Senior Advisor for BCT Consulting since 2008. She works as an advisor to biotech companies providing consultant services specializing in Clinical Research. She received her PhD in Clinical Immunology at the University of Gothenburg in 1986 and joined the pharmaceutical industry in 1989. She has specialized in the development of pharmaceuticals and medical products with a focus on clinical trials. She has over 20 years of experience in senior management positions in international companies such as GlaxoWelcome, Bayer, NMCT, and Quintiles. Helena is the author of “Guide to the Implementation of the Clinical Trials” and educates in this area. She has been a board member of the Swedish Pharmaceutical Society for Clinical Trials from 1997 to 2009 and was its chairman from 2006 to 2009. Helena Lomberg is also a board member of Hamlet Pharma AB.
Bachelor of Art – Economics and Political science from University of Lund. PR and communication consultant with more than 30 years experience as advisor within strategic communication. Senior Vice President Corporate Communications for the pharmaceutical groups Kabi and Kabi Pharmacia, Vice President Procordia Eurocentre in Brussels and Senior Vice President Corporate Communications for Atlas Copco including responsibility for Investor Relations together with the CFO. Carl-Johan has been strategic advisor for a considerable number of listed companies.
Björn Kettilsson Wullt
Associate Professor of Microbiology, Lund University, and senior consultant in Urology. Board member of the European Association of Urology Infection Society and member of several international Guide Line Panels for Urinary Tract Infections. Owner of a clinical trial unit specialized in conducting clinical research for pharmaceutical companies.
Chief Executive Officer, CEO
MBA from the Stockholm School of Economics and Business Administratiom. Has held several leading positions in various industries and companies, among others. as Corporate Treasurer of KABI and CFO of KABI Biopharma, that later merged with Pharmacia and nowadays is a part of Pfizer, Corporate Treasurer of SAAB Automobile, CEO of Nova Medical Calab, a company that acquired and operated clinical laboratories and that now is a part of Unilab, Wilh. Sonesson, whom he as CEO re-introduced on the Stockholm Stock Exchange in 1999 and CEO of Hamlet Pharma a company that Catharina Svanborg and Fredrik Herslow listed on Spotlight Stock Market 2015.
Bachelor of Laws. During 1983-2011, he held a number of senior positions within the AstraZeneca legal department, including Vice President, Strategy, Intellectual Property, Assistant General Counsel and as Head of Group Branding. Possesses over 35 years of experience in negotiation, agreements on technology transfer and licenses, commercialization of products, patent strategies, company and project transactions, due diligence and intellectual property rights. Since 2012, he has its own legal consultancy firm focusing on life science.
Chief Medical Officer, CMO
Erik Sturegård is an MD, PhD with specialist degrees in both clinical bacteriology and clinical virology. He splits his worktime between a position as senior consultant at the clinical microbiology department and a position as associate professor in medical microbiology at Lund University. He has many years of research experience in microbiology, doing laboratory based studies as well as epidemiological investigations.
Has a master’s degree in Bioengineering from the University of Toulouse, France and is a senior PhD student in Biomedicine. Her research focuses on understanding molecular mechanisms of infection and to develop novel therapeutic targets, preventive strategies and biomarkers markers of susceptibility.
Translational Research coordinator
Received his master’s degree in biomedicine from Lund University and is a senior PhD student. He is currently a senior PhD student focusing on molecular characterization of acute cystitis and novel treatment approaches to urinary tract infections.
Thi Hien Tran
Obtained her PhD degree in pharmacology in 2013 from Yeungnam University South Korea and moved to Lund in 2013 for a postdoc. From 2016, she holds a position as a research scientist, focusing on drug discovery, especially in vivo models.
Works at the Department of Paediatrics, Skåne University Hospital and is PhD student at Lund University. She is coordinating a multicentre study of febrile infections in infants and young children, which will generate biomarkers for infectious disease susceptibility. The study addresses clinical and molecular genetic susceptibility factors in infants with urinary tract infections and kidney damage.
Holds a PhD in Toxicology from the University of Hong Kong, 2015. Postdoctoral fellow at the University of Hong Kong and visiting scholar at the University of British Columbia on food toxicology and microbiology. Currently at Lund University as a postdoctoral fellow, focusing on novel therapies for bacterial infections.
Holds a PhD in pharmaceutics from Yeungnam University, Korea and has over 5 years of experience in developing novel therapies for infection and cancer. He is a research scientist in Lund University, Sweden. Dr. Tran has authored a number of papers in prestigious journals.